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Hepatitis C virus (HCV) infection is dependent on at least three coreceptors: CD81, scavenger receptor BI
(SR-BI), and claudin-1. The mechanism of how these molecules coordinate HCV entry is unknown. In this
study we demonstrate that a cell culture-adapted JFH-1 mutant, with an amino acid change in E2 at position
451 (G451R), has a reduced dependency on SR-BI. This altered receptor dependency is accompanied by an
increased sensitivity to neutralization by soluble CD81 and enhanced binding of recombinant E2 to cell
surface-expressed and soluble CD81. Fractionation of HCV by density gradient centrifugation allows the
analysis of particle-lipoprotein associations. The cell culture-adapted mutation alters the relationship between
particle density and infectivity, with the peak infectivity occurring at higher density than the parental virus. No
association was observed between particle density and SR-BI or CD81 coreceptor dependence. JFH-1 G451R
is highly sensitive to neutralization by gp-specific antibodies, suggesting increased epitope exposure at the
virion surface. Finally, an association was observed between JFH-1 particle density and sensitivity to neutral-
izing antibodies (NAbs), suggesting that lipoprotein association reduces the sensitivity of particles to NAbs. In
summary, mutation of E2 at position 451 alters the relationship between particle density and infectivity,
disrupts coreceptor dependence, and increases virion sensitivity to receptor mimics and NAbs. Our data
suggest that a balanced interplay between HCV particles, lipoprotein components, and viral receptors allows
the evasion of host immune responses.
Hepatitis C virus (HCV), the sole member of the Hepacivi-
rus genus within the Flaviviridae, poses a global health burden,
with an estimated 170 million infected individuals (according
to the WHO). The majority of patients suffer a chronic infec-
tion that is associated with a progressive liver disease (1). HCV
has a short positive-sense RNA genome encoding three struc-
tural (core protein, E1, and E2) glycoproteins (gps) and seven
nonstructural proteins (p7 and NS2 to NS5) (40). The E1 and
E2 gps interact with cell surface receptors to facilitate particle
entry via low-pH and clathrin-dependent endocytosis (9, 15, 29,
47, 71). The recent discovery that the JFH-1 strain of HCV can
replicate and assemble infectious particles in cultured cells
(HCVcc) has allowed investigation into the viral life cycle for
the first time since its identification almost 20 years ago (41, 75,
79).
Early studies with truncated soluble HCV E2 (sE2) identi-
fied interactions with the tetraspanin CD81 and scavenger re-
ceptor class B type I (SR-BI) (56, 62). The recent availability of
HCVcc and HCV pseudoparticles (HCVpp) provided the tools
to validate receptor candidates. HCV entry is thought to re-
quire at least three cellular receptors: CD81, SR-BI, and the
tight junction protein claudin-1 (reviewed in references 21 and
74). Other candidate components include glycosaminoglycans
(5, 6, 51), low-density lipoprotein receptor (49, 77), and the
C-type lectins DC-SIGN (dendritic cell-specific ICAM-3-grab-
bing nonintegrin) and L-SIGN (liver/lymph node-specific
ICAM-3-grabbing nonintegrin) (37, 42, 43, 58). HCVpp dem-
onstrate a restricted entry into human cells of liver origin (7,
29), suggesting that gp-receptor interaction(s) may in part de-
fine HCV tropism for the liver.
CD81, a tetraspanin, is expressed throughout the body; it
facilitates the formation of highly ordered protein complexes
at the plasma membrane and regulates multiple signaling path-
ways important for cell-cell adhesion, migration, activation,
and proliferation (reviewed in reference 39). Expression of
CD81 in CD81-negative human liver cells allows HCV infec-
tion, demonstrating a critical role for CD81 in viral entry (29,
38, 41). Viral entry is dependent on the large extracellular loop
(LEL) of CD81, and antibodies that perturb this interaction
neutralize viral infectivity (24, 25, 29, 33, 34, 54).
SR-BI, also known as CLA-1, is expressed predominantly in
the liver and steroidogenic tissue, where it mediates the selec-
tive uptake of cholesterol from ligands such as high-density
lipoprotein (HDL) (reviewed in references 36 and 64). HCV
E2 interaction with SR-BI is believed to occur via hypervari-
able region 1 located within the N-terminal region of the E2
glycoprotein (8, 62). Native lipoprotein ligands, HDL and ox-
idized low-density lipoprotein, enhance and inhibit HCV in-
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fection, respectively, suggesting a complex interplay between
SR-BI, lipoproteins, and HCV (8, 72, 73). Transduction of
Huh-7.5 cells to overexpress SR-BI enhanced HCV entry, sug-
gesting that SR-BI levels limit viral entry (27). Anti-SR-BI
antibodies and small interfering RNA silencing of SR-BI ex-
pression perturb HCV infection (12, 27), and recent data dem-
onstrate that antibodies specific for SR-BI and CD81 inhibit
JFH-1 infectivity in a synergistic manner, suggesting cooperat-
ivity between the receptors (31, 78).
There has been a steady accumulation of evidence to suggest
that lipoproteins play a key role in the HCV life cycle. Early
observations with plasma from infected individuals reported
that antibodies specific for the apoprotein component of very-
low-density lipoprotein (VLDL) could precipitate HCV RNA,
suggesting an association of viral particles with host lipopro-
teins (2, 52, 53, 67, 68). Recent studies with HCVcc have
reported virion assembly to be intrinsically linked to VLDL
synthesis, suggesting that HCV may be incorporated into lipo-
viro-particles (LVPs) during assembly or release (13, 26, 30).
Several reports demonstrate that anti-apoprotein antibodies
inhibit HCV infection, lending further support for a role of
lipoproteins in HCV LVP entry (3, 13).
Several groups have characterized the adaptation of JFH-1
and intergenotypic chimeras, resulting in the selection of vi-
ruses with enhanced replicative potential (10, 32, 60, 80).
Zhong and colleagues reported that a glycine-to-arginine mu-
tation at position 451 (G451R) in E2 promoted JFH-1 infec-
tivity (80). Our studies with JFH-1 G451R demonstrate a re-
duced dependency on SR-BI and increased binding to CD81.
Analysis of HCV buoyant density as a measure of lipoprotein
association demonstrated an altered relationship between par-
ticle density and infectivity of the mutant virus, with the peak
JFH-1 G451R infectivity occurring at higher density than pa-
rental virus. The mutation also increased the sensitivity of
particles to neutralization by gp-specific antibodies, suggesting
an increased availability of epitopes on the mutant particle. An
association was noted between JFH-1 density and sensitivity to
neutralizing immunoglobulin G (IgG), suggesting that lipopro-
teins reduce the sensitivity of particles to neutralizing antibod-
ies (NAbs). These data support a model where mutation of E2
at position 451 alters gp structure, modulating viral interaction
with coreceptors and NAbs and disrupting the relationship
between particle density and infectivity.
MATERIALS AND METHODS
Cells and antibodies. 293T and Chinese hamster ovary (CHO) cells were
obtained from the American Type Culture Collection and propagated according
to the supplier’s recommendations. Huh-7.5 cells (provided by Charles Rice, The
Rockefeller University, New York, NY) (10) were propagated in Dulbecco’s
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% nonessential amino acids. All cells were grown at 37°C in 5% CO2.
CHO cells stably expressing SR-BI were generated and propagated as previously
described (44). CHO cells stably expressing CD81 were generated by transfection
with a pCDNA3.1 plasmid vector encoding human CD81. Anti-SR-BI serum was
generated as previously reported (44), and anti-CLA-1 monoclonal antibody
(MAb) was obtained from BD biosciences. Anti-CD81 MAbs (2s131, 1s201, and
2s139) were generated by immunizing mice with full-length CD81. Soluble hu-
man CD81 (hCD81) LEL was generated as reported by Drummer and coworkers
(19, 20). Polyclonal IgG was isolated from healthy donors and chronically HCV-
infected patient serum using protein G-conjugated Sepharose beads (GE
Healthcare, United Kingdom). MAbs 3/11 and 10/76b were generated as previ-
ously described (24, 63).
Transduction of cells to overexpress SR-BI. TRIP lentiviruses expressing
SR-BI were generated in 293T cells as previously reported (27). Briefly, Huh-7.5
cells were seeded at 8  105 cells per well of a six-well plate and infected 24 h
later with the packaged lentivirus diluted in DMEM supplemented with 3% FBS.
After 12 h, cells were washed, trypsinized, and seeded into appropriate plates for
HCV infection. Flow-cytometric analysis demonstrated that Huh-7.5 TRIP-
SR-BI cells expressed twofold more SR-BI than parental cells.
HCVcc genesis, infection, and neutralization assays. JFH-1 and G451R vi-
ruses were generated as previously described (40). Briefly, RNA was transcribed
in vitro from full-length genomes using a Megascript T7 kit (Ambion, Austin,
TX) and electroporated into Huh-7.5 cells. Virus was harvested from cells within
10 days postelectroporation. Huh-7.5 cells were seeded at 1.5 104 cells per well
in 48-well plates and infected the following day with JFH-1 wild-type (wt) or
G451R particles diluted in 3% FBS–DMEM. At 48 h postinoculation infection
was detected by methanol fixation and staining for NS5A antigen with anti-NS5A
MAb 9E10 and AlexaFluor 488-conjugated anti-mouse IgG (Invitrogen, CA)
(40). Infections were quantified by enumerating the total number of infected
cells per well, and the results were used to calculate the number of infectious
units per ml (IU/ml) of virus inoculum. For neutralization and receptor blocking
assays, virus or cells were preincubated at 37°C for 1 h with the appropriate
inhibitory or control antibody prior to infection. In each case the initial virus
inoculum was diluted to approximately 2,000 IU/ml. The percent neutralization
of test treatments was expressed relative to control irrelevant antibody-treated
infections. Typical JFH-1 wt and G451R infectivities were 2,500 and 10,000
IU/ml, respectively, corresponding to an infected-cell count of 100 to 200 cells/
well at the dilutions tested.
Quantification of HCV particle buoyant density. HCVcc virus was concen-
trated 50-fold using a Vivaspin 20 column with a 100-kDa cut off (Sartorius,
Germany). Linear iodixanol (Axis-Shield, United Kingdom) gradients were pre-
pared using a two-chamber gradient maker (Jencons, United Kingdom) with
light (6%) and dense (56%) iodixanol solutions (53). Gradients were used im-
mediately after preparation, and 0.4 ml of concentrated virus was loaded onto
each gradient. Samples were centrifuged at 100,000  g for 21 h at 4°C in an
L80-M ultracentrifuge (Beckman, United Kingdom); fractions were harvested,
and their densities were determined with a digital refractometer (Atago, Japan).
Quantification of HCV RNA. RNA was extracted using an RNeasy Mini Kit
(Qiagen, Germany) or QIAamp MinElute virus kit (Qiagen, Germany), accord-
ing to manufacturer’s instructions. The amplification efficiency of cell-free HCV
RNA preparations was assessed by the addition of a small quantity of exogenous
HeLa RNA (10 pg) to the reverse transcription-PCR (RT-PCR) mixture. HCV
amplification was performed using a modification of a previously described
method (16, 66) in accordance with the manufacturer’s guidelines (CellsDirect
kit, Invitrogen, CA). Fluorescence was monitored in a 7900 HT real-time PCR
machine (ABI, CA) (46). In all reactions the housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase was included as an internal endogenous control for
amplification efficiency and RNA quantification (primer-limited endogenous
control; ABI).
Immunofluorescent microscopy. CHO cells expressing SR-BI or CD81 were
fixed in ice-cold methanol for 5 min, blocked with 5% bovine serum albumin–
phosphate-buffered saline (PBS), and stained with 0.1 g/ml anti-CLA-1 (SR-BI)
or 2s139 (CD81); bound antibody was detected with an AlexaFluor 488-conju-
gated anti-mouse IgG (Invitrogen, CA). Images were taken at a magnification of
200 with a TE2000-S microscope using a Hamamatsu C4742-65 camera
(Nikon, Japan).
Expression of soluble truncated HCV E2. The nucleotide sequence encoding
amino acids 384 to 661 of the HCV polyprotein was amplified from a cDNA
clone of JFH-1 or G451R, and the products were cloned into pcDNA3.1 down-
stream of the tissue plasminogen activator leader sequence. The reverse primer
encoded a C-terminal human immunodeficiency virus (HIV) gp120 epitope tag,
recognized by MAb 10/76b. Plasmids were introduced into 293T cells with Pro-
Fection (Promega, WI), and the sE2 was harvested from cells propagated in
DMEM supplemented with 3% delipidated FBS at 48 and 72 h posttransfection.
The relative concentrations of sE2 preparations were quantified by enzyme
immunoassay using MAb 10/76b, as previously reported (45).
Quantification of sE2 coreceptor interactions. Soluble JFH-1 wt and G451R
E2 (sE2) were diluted to the same relative concentrations and assayed for their
ability to bind SR-BI and CD81, as previously reported (24, 73). Briefly, sE2 was
incubated at 37°C with parental CHO cells or with cells expressing SR-BI/CD81
for 1 h, and bound E2 was detected with MAb 10/76b and AlexaFluor 488-
conjugated anti-rat IgG (Invitrogen, CA). Samples were quantified on a FACS-
Calibur flow cytometer (BD Biosciences), and the data were analyzed with
FlowJo software (Tree Star, San Carlos, CA). sE2 interaction with hCD81 LEL
was quantified by enzyme-linked immunosorbent assay, as previously reported
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(20, 24). Briefly, Immulon 2HB enzyme-linked immunosorbent assay plates
(Thermo, MA) were coated overnight with hCD81 LEL at 0.5 g/well, blocked
with 5% bovine serum albumin–PBS, and incubated with sE2 for 4 h at 37°C.
Bound E2 was detected with MAb 10/76b and horseradish peroxidase-conju-
gated donkey anti-rat IgG (Jackson Immunoresearch, United Kingdom). Bound
horseradish peroxidase conjugates were detected colorimetrically after reaction
with a TMB (3,3,5,5-tetramethylbenzidine) substrate solution (Biofix, MD).
RESULTS
JFH-1 G451R has a reduced dependence on SR-BI. We
previously reported that overexpression of SR-BI in Huh-7.5
cells enhanced JFH-1 entry (27). To investigate whether the
adaptive mutation affects JFH-1 interaction(s) with SR-BI,
parental Huh-7.5 cells and cells transduced to overexpress
SR-BI were infected with JFH-1 wt and G451R. We previously
reported that HCV can infect hepatoma cells via cell-free and
cell-cell routes (69). To discriminate between cell-free particle
primary infection and secondary transmission events, infection
was allowed to proceed for 48 and 72 h, respectively (69).
Overexpression of SR-BI enhanced the infectivity of JFH-1
fourfold at 48 h postinfection, and this increased to eightfold
by 72 h (Fig. 1A). At 72 h the increased infectivity was asso-
ciated with a doubling in the number of infected cells per focus
(data not shown), suggesting increased cell-cell transfer of
infection. In contrast, JFH-1 G451R showed a 1.5-fold increase
in infectivity at both time points with no change in focal size
(Fig. 1A).
To further investigate JFH-1 G451R interaction(s) with SR-
BI, we employed a neutralizing rabbit anti-SR-BI serum capa-
ble of inhibiting HCV infectivity and preventing sE2 interac-
tion with SR-BI (27, 44). Huh-7.5 cells were preincubated with
the anti-SR-BI serum prior to challenge with JFH-1 wt or
G451R. While the infectivity of both viruses was inhibited,
JFH-1 G451R is less sensitive to neutralization; a 1/100 dilu-
tion of antiserum reduced JFH-1 G451R infectivity by 20%,
compared to 80% for wt virus (Fig. 1B).
It is widely reported that HDL enhances HCV infection via
an SR-BI-dependent mechanism requiring the transfer of lip-
ids from HDL (8, 17, 72). To ascertain whether the altered
relationship of G451R with SR-BI extends to lipoprotein en-
hancement, JFH-1 wt and G451R infections were supple-
mented with 10 g/ml HDL. HDL promoted JFH-1 wt infec-
tivity twofold, consistent with previous reports; however,
G451R infectivity was unaltered (Fig. 1C). Taken together,
these data suggest that cell culture adaptation reduces the
requirement for SR-BI during virus entry.
JFH-1 G451R has an increased sensitivity to neutralization
by soluble CD81. Having established that the G451R mutation
alters the relationship between HCV and SR-BI, we wanted to
investigate the effects of this mutation on CD81-dependent
routes of entry. Huh-7.5 cells were incubated with anti-CD81
MAbs prior to infection with JFH-1 wt or G451R. The infec-
tivity of both viruses was reduced by the anti-CD81 MAbs;
however, JFH-1 G451R was less sensitive to treatment by anti-
CD81 MAbs (Fig. 2A and B). We along with other investiga-
tors have reported that a soluble form of hCD81 LEL interacts
with the viral gps and inhibits HCV infectivity (7, 25, 29, 40,
50). JFH-1 G451R demonstrated increased sensitivity to neu-
tralization by hCD81 LEL, with 10-fold less protein required to
reduce infectivity by 50% (Fig. 2C), suggesting an increased
exposure or affinity of CD81 binding residues on the mutant
viral gps.
JFH-1 G451R sE2 demonstrates increased binding to CD81.
To investigate whether the G451R mutation modulates E2
binding to SR-BI or CD81, soluble forms of JFH-1 wt and
G451R E2 were expressed in 293T cells and used to quantify
receptor interactions. sE2 was harvested from the medium of
cells supplemented with 3% delipidated FBS to eliminate the
possibility of lipoprotein association(s). CHO cells expressing
either human SR-BI (CHO-SR-BI) or CD81 (CHO-CD81)
(Fig. 3A) were incubated with equal amounts of JFH-1 wt or
G451R sE2; the bound gps were detected via a C-terminal tag
recognized by MAb 10/76b and quantified by flow cytometry
(Fig. 3B). JFH-1 wt sE2 bound specifically to CHO cells ex-
pressing either SR-BI or CD81, as previously reported for
genotype 1 sE2 (24, 27, 62). JFH-1 wt and G451R sE2 bound
to CHO-SR-BI cells with comparable staining intensities; how-
ever, the mutant protein showed enhanced binding to CD81,
with 50% more CHO-CD81 cells binding G451R sE2 than
JFH-1 wt (Fig. 3B and C). These data are consistent with the
increased sensitivity of mutant virus to hCD81 LEL neutral-
ization.
To study further the interaction of wt and G451R sE2 with
CD81, we followed the binding of sE2 with hCD81 LEL by
enzyme immunoassay. Previous studies have reported that E2
interaction with CD81 is dependent on the dimeric status of
CD81 (19, 20). CD81 dimers bound approximately threefold
FIG. 1. JFH-1 G451R has an altered dependence on SR-BI. (A) Huh-7.5 cells overexpressing SR-BI were incubated with JFH-1 wt or JFH-1
G451R for 8 h. Cells were fixed after 48 and 72 h and stained for NS5A, and the mean number of infected cells per well was determined. Infectivity
is expressed relative to parental Huh-7.5 cells. (B) Huh-7.5 cells were incubated with a serial dilution of rabbit anti-SR-BI serum for 1 h prior to
challenge with JFH-1 wt or JFH-1 G451R. The data are expressed as percent neutralization relative to infection of Huh-7.5 cells treated with
control rabbit serum. (C) Huh-7.5 cells were inoculated with JFH-1 wt or JFH-1 G451R in the presence of 10 g/ml HDL. Infection is expressed
relative to infection in the absence of HDL. Error bars indicate standard deviation from the mean (n  3; P  0.0069, unpaired t test).
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more JFH-1 G451R than wt sE2 (Fig. 4A), confirming our
earlier studies with CHO cell-expressed CD81. hCD81 LEL
monomers failed to interact with wt or mutant sE2 (Fig. 4B).
To further characterize the interaction of G451R sE2 with
hCD81 LEL, we compared mutant and wt sE2 interactions
with a panel of CD81 variants with substitutions at amino acid
residues reported to be critical for interacting with E2 (20). All
mutations abrogated CD81 interaction with both wt and
G451R sE2 proteins, suggesting that the G451R mutation does
not alter the nature of the E2-CD81 interaction (Fig. 4B).
Relationship between JFH-1 and G451R particle density,
infectivity, and coreceptor interactions. HCV particles associ-
ate with lipoproteins to form LVPs that can be fractionated
according to their buoyant density. (2, 40, 41, 48, 53, 67). Initial
experiments examined the distribution of wt and mutant par-
ticles across iodixanol gradients by quantifying genome copy
numbers in each fraction. wt and mutant viruses demonstrated
a similar range of particle densities, suggesting comparable
physical properties (Fig. 5A). Low-density particles are re-
ported to have the highest specific infectivity (40, 41); in sup-
FIG. 3. Interaction of JFH-1 wt and G451R sE2 with CHO cells express-
ing SR-BI and CD81. (A) CHO-SR-BI cells (80% positive) or CHO-CD81
cells (20 to 30% positive) were methanol fixed and stained with MAb anti-
CLA1 or anti-CD81 2s139. (B) Binding of recombinant JFH-1 wt and G451R
sE2 to parental CHO cells and CHO-SR-BI and CHO-CD81 cells. Bound
E2 was detected with MAb 10/76b. (C) The mean fluorescence intensity
(MFI) of JFH-1 wt and G451R sE2 bound to CHO-SR-BI and CHO-CD81
cells is shown; the signal from the sE2-CHO cell interaction was subtracted.
Error bars indicate standard deviation from the mean (n  3).
FIG. 2. CD81 dependence of JFH-1 wt and G451R infection. Huh-
7.5 cells were incubated with a serial dilution of 2s131 (A) or 1s201
(B) mouse anti-CD81 MAb for 1 h prior to challenge with JFH-1 wt
(filled circles) or JFH-1 G451R (open circles). (C) JFH-1 wt or G451R
viruses were incubated with human CD81 LEL for 1 h prior to infec-
tion of Huh-7.5 cells. The data are expressed as percent neutralization
relative to viral infection in the presence of an irrelevant mouse IgG or
nonactive mouse CD81 LEL, respectively. Error bars indicate standard
deviation from the mean (n  3).
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port of this we observed peak JFH-1 wt infectivity at a density
of 1.09 g/ml (Fig. 5B). In contrast, the majority of JFH-1
G451R infectivity resided in the higher-density fractions at
1.12 g/ml (Fig. 5B), suggesting an altered relationship between
particle density and infectivity. The RNA copy number and
infectivity data were used to calculate the specific infectivities
of particles within each fraction; the G451R adaptation ap-
pears to have increased the infectivity of higher-density parti-
cles while perturbing the infectivity of low-density particles
(Fig. 5C).
To study the relationship between particle density and re-
ceptor-dependent infection, JFH-1 wt and G451R iodixanol
gradient fractions were screened for infection of parental and
Huh-7.5 cells transduced to overexpress SR-BI and for their
sensitivity to neutralization by SR-BI- and CD81-specific anti-
bodies (Fig. 6). We failed to observe any association between
wt or mutant virus density and SR-BI dependence, with all
fractions showing comparable levels of infectivity under the
respective conditions (Fig. 6A and B). JFH-1 G451R demon-
strated a lower dependence on SR-BI, with minimal inhibition
observed with the anti-SR-BI antibody (Fig. 6B). Similar re-
sults were observed with the anti-CD81 MAb, with all fractions
demonstrating a similar sensitivity to neutralization (Fig. 6C).
The lack of correlation between JFH-1 wt and G451R particle
density and sensitivity to antireceptor antibodies suggests that
the mutant phenotype of reduced SR-BI dependence and in-
creased sensitivity to hCD81 LEL neutralization may be largely
attributable to an altered affinity or interaction of the viral gps
with CD81 (Fig. 3 and 4).
JFH-1 G451R demonstrates an increased sensitivity to
NAbs. Several reports have suggested that antibodies specific
for the HCV gps neutralize viral infectivity by inhibiting HCV
interaction(s) with CD81 (33, 34, 55) (reviewed in reference
65). Given the increased binding of G451R E2 to CD81, we
were interested to investigate the effects of this mutation on
particle sensitivity to NAbs. We screened the sensitivity of
JFH-1 wt and G451R virus to neutralization by IgG purified
from the sera of six HCV-infected individuals. In each case
G451R demonstrated an increased sensitivity to inhibition by
patient IgG (Fig. 7A to F). JFH-1 wt was inhibited to various
degrees by the patient IgG, and in five of six cases the percent
neutralization reached a plateau below 80%, suggesting that a
population of particles was resistant to neutralization. To
quantify the increased sensitivity of G451R to antibody-depen-
dent neutralization, we determined the concentration of
pooled HCV-positive(HCV) patient IgG required to inhibit
50% of infectivity (50% inhibitory concentration [IC50]). The
IC50s for the wt and mutant viruses are 40 g/ml and 0.75
FIG. 4. Interaction JFH-1 wt and G451R sE2 with recombinant CD81. (A) Dose-dependent binding of JFH-1 wt (gray bars) or G451R (white
bars) sE2 with hCD81 LEL dimer. Data are represented as the mean optical density (OD) at 450 nm. (B) JFH-1 wt or G451R sE2 association with
PBS, monomeric and dimeric hCD81 LEL, and mutants of hCD81 LEL that abrogate CD81 interaction with E2. All mutants were characterized
for their effects on CD81 oligomerization and were shown to have minimal effect on dimerization. E2 binding to the mutants is expressed relative
to CD81 LEL dimer. Error bars indicate standard deviation from the mean (n  3).
FIG. 5. Analysis of JFH-1 wt and G451R buoyant density. Concen-
trated JFH-1 wt and G451R were separated on an iodixanol gradient.
(A) The number of HCV particles per fraction was assessed by quan-
tifying HCV RNA genomes by RT-PCR. The particle number in each
fraction is expressed as a percentage of the total for either virus.
(B) The infectivity per fraction was assessed by inoculating Huh-7.5
cells. The infectivity within each fraction is expressed as a percentage
of the total for either virus. Error bars indicate standard deviations
from the mean (n  3). (C) The number of infectious units per RNA
genome copy were calculated to analyze the specific infectivity of
particles within each fraction.
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g/ml, respectively, indicating that G451R is 50-fold more sen-
sitive to neutralization (Fig. 7G). Patient-derived IgG is poly-
clonal in nature and likely to target multiple conformation-
dependent epitopes. To study virus neutralization via a defined
epitope, we screened the sensitivity of both viruses to MAb
3/11, specific for E2 amino acids 412 to 423. G451R showed an
increased sensitivity to MAb 3/11 neutralization (Fig. 7H).
These data are consistent with an increased sensitivity of
G451R particles to NAbs targeting diverse epitopes, suggesting
an increased availability of epitopes on G451R compared to
the parental virus. However, we failed to detect any difference
in HCV patient IgG or MAb 3/11 binding to immobilized
JFH-1 wt or G451R sE2 or to infected cells by flow cytometry,
suggesting that differential epitope presentation may occur in
the context of a virus particle.
To investigate whether the increased sensitivity of G451R to
NAbs was attributable to alterations in particle density, the
iodixanol gradient fractions of wt and mutant viruses were
normalized for infectivity and incubated with 10 g/ml pooled
HCV patient IgG. For JFH-1 wt, the sensitivity to neutral-
ization increased with particle density such that the lower-
density fraction was neutralized by 20% and the higher-density
fraction by 80% (Fig. 8). In contrast, all G451R fractions were
neutralized by 100%. Control experiments established that io-
dixanol concentration had minimal effects on JFH-1 infectivity
and sensitivity to IgG neutralization (data not shown). These
data provide the first evidence that lipoprotein association of
JFH-1 reduces the sensitivity of particles to NAbs; however,
the increased infectivity of high-density G451R viruses does
not explain their heightened sensitivity to antibody-dependent
neutralization.
DISCUSSION
We have demonstrated that a cell culture-adaptive mutation
in E2 has pleiotropic effects on HCV interaction(s) with SR-
BI, CD81, and NAbs. JFH-1 G451R infectivity was not en-
hanced in Huh-7.5 cells transduced to overexpress SR-BI and
was insensitive to anti-SR-BI and HDL treatments (Fig. 1),
suggesting a reduced requirement for SR-BI during entry. De-
finitive evidence of SR-BI independence is hampered by the
lack of SR-BI-negative permissive cell lines. We failed to de-
tect any effect(s) of the G451R mutation on sE2 interaction
with CHO cells expressing SR-BI (Fig. 3B and C); however,
soluble forms of E2 may not recapitulate the interaction of
virus particles with SR-BI.
CD81 is a critical coreceptor for HCV particle entry (40, 45).
The mutant virus demonstrated a 10-fold increase in the sen-
sitivity to neutralization by hCD81 LEL, suggesting an in-
creased affinity of the gps for CD81 (Fig. 2C). Indeed, G451R
sE2 demonstrated increased binding to CHO-CD81 cells and
hCD81 LEL, supporting this conclusion (Fig. 3 and 4). The
observation that G451R demonstrated reduced sensitivity to
neutralization by anti-CD81 MAbs relative to wt virus is con-
sistent with an increased affinity of G451R glycoproteins that
are able to more effectively compete with subsaturating levels
of MAbs than wt for cell surface-expressed CD81 (Fig. 2A and
B). Mutations in CD81 reported to prevent interaction with E2
(20) abolished the binding of both JFH-1 wt and G451R sE2
(Fig. 4B), suggesting that the interface between JFH-1 G451R
E2 and CD81 is unaltered and that the viral phenotype may
simply reflect a greater affinity of the gp with the coreceptor.
Studies with HCVpp suggest that the CD81 binding site on E2
involves three discontinuous regions (18, 55, 59), and G451R is
located immediately downstream of one such region, G436W
LAGLFY (18). Thus, the adaptive mutation may directly mod-
ulate E2 affinity for CD81. Our data suggest an important role
for position 451 in JFH-1 E2 coordination of particle interac-
tion with SR-BI and CD81 and highlight the importance of
studying mutant gp association with multiple viral coreceptors.
Numerous reports have used density gradient centrifugation
to study the association of plasma or serum-derived HCV with
the major VLDL apoproteins (ApoB-100 and ApoE) (2, 53,
68). Recent data implicate VLDL synthesis in HCV particle
assembly and/or release, suggesting that HCVcc particles in-
teract with lipoproteins in an analogous manner to blood-
derived virus (13, 26, 30, 41). Nielsen et al. reported that
iodixanol density gradient centrifugation preserved HCV
VLDL interactions (53), and we employed this technique to
investigate the relationship between JFH-1 particle density and
FIG. 6. Relationship between particle density and coreceptor de-
pendency. The density fractions containing infectious JFH-1 wt or
JFH-1 G451R were used to assess the relationship between particle
density and SR-BI and CD81 interaction(s). The approximate densities
of each fraction are indicated on the x axis. (A) Huh-7.5 cells overex-
pressing SR-BI were inoculated with JFH-1 wt and G451R virus, and
infectivity is expressed relative to parental Huh-7.5 cells. Huh-7.5 cells
were incubated with either anti-SR-BI serum at 1/300 (B) or anti-
CD81 1s201 at 0.1 g/ml (C) prior to challenge with infectious frac-
tions of JFH-1 wt and G451R. Error bars indicate standard deviations
from the mean (n  3).
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FIG. 7. JFH-1 G451R demonstrates an increased sensitivity to neutralization by gp-specific antibodies. JFH-1 wt (closed circles) or G451R (open circles)
was incubated with IgG purified from the sera of six HCV-infected subjects (A to F) or anti-E2 MAb 3/11 (H) prior to infection of Huh-7.5 cells. Percent
neutralization was calculated by quantifying viral infectivity in the presence of anti-HCV-specific antibodies relative to HCV-negative IgG or irrelevant MAb,
respectively. (G) To determine the concentration of IgG required to neutralize 50% of JFH-1 and G451R infectivity (IC50), both viruses were incubated with
a pool of the six-patient-derived IgG. The IC50 is depicted as a horizontal line. Error bars indicate standard deviations from the mean (n  3).
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infectivity. Zhong et al. reported an altered relationship be-
tween JFH-1 G451R buoyant density and infectivity, with high-
density mutant virus demonstrating greater infectivity than wt
(80). Similar data were observed with iodixanol density gradi-
ent separation (Fig. 5B). Importantly, analysis of particle num-
ber(s) by quantitative RT-PCR demonstrated a comparable
distribution of wt and mutant viruses (Fig. 5A), suggesting that
both viruses associate with lipoproteins in a comparable
manner. Analysis of specific infectivity throughout the density
gradient suggests that the G451R mutation increases the in-
fectivity of higher-density particles while reducing that of low-
density particles (Fig. 5C). Determining how the cell culture
adaptation alters the relationship between particle density and
infectivity will require a better understanding of the contribu-
tion that lipoprotein components make to particle infectivity.
Lipoproteins have been implicated in HCV entry and par-
ticle interaction(s) with SR-BI (3, 13, 44). However, we failed
to observe any association between infectious particle density
and responsiveness to SR-BI overexpression or receptor “neu-
tralization” for JFH-1 wt or G451R (Fig. 6). These data do not
discount the role of lipoproteins in the primary engagement
between virus and receptors; however, it suggests that the
“functional outcome,” i.e., entry, is principally driven by the
viral gps. HCVpp assembly and entry are less dependent on
host lipoproteins and offer a tool to dissect the role of the
adaptive G451R mutation in viral entry. However, E1E2 gps
with the G451R mutation failed to generate infectious HCVpp
(data not shown).
The heightened sensitivity of JFH-1 G451R to neutralization
is not confined to hCD81 LEL; IgG from six HCV-infected
individuals inhibited JFH-1 G451R 50-fold more effectively
than wt (Fig. 7A to G). The polyclonal IgG was isolated from
patients infected with HCV genotypes 1 or 3 and most likely
reflects a mixture of antibodies specific for diverse conforma-
tion-dependent epitopes. In addition, G451R was 10-fold
more sensitive to neutralization by anti-E2 MAb 3/11 (Fig.
7H), which is specific for amino acids 412 to 423 (29, 55).
Experiments to assess the binding of polyclonal HCV patient
IgG and MAb 3/11 to immobilized JFH-1 wt and G451R sE2
by enzyme immunoassay found no differences (data not
shown). However, sE2 may not be an accurate mimic of
epitope availability in a native virus particle (14, 25, 35).
We hypothesized that virus association with lipoproteins re-
duces the efficacy of NAbs. Taking particle density as a mea-
sure of lipoprotein interaction(s), we demonstrate that low-
density JFH-1 has reduced sensitivity to HCV patient IgG
neutralization (Fig. 8), showing a range of neutralization val-
ues from 20 to 80% between the densities of 1.04 to 1.14 g/ml.
The data support a model where lipoproteins obscure critical
epitopes from NAbs, and, since the majority of infectious
JFH-1 particles are of low density, this may explain their in-
sensitivity to NAbs (Fig. 7). The mechanism by which this
occurs is unknown; however, lipoproteins may restrict the ac-
cess of antibodies to E2 or promote the stabilization of virus
particles. Our findings are consistent with observations with
serum-derived HCV (2, 41, 67) and with the findings of Thom-
msen et al., who reported that ApoB-100-associated virus
failed to precipitate with polyclonal IgG (68). Similarly, Molina
et al. reported that serum virus infectivity was neutralized with
anti-CD81 antibodies targeting the host cell whereas infectivity
was resistant to hCD81 LEL, suggesting reduced exposure of
CD81 binding epitopes on circulating particles (50).
The majority of patient-derived HCV strains have proven
difficult to propagate in vitro. In this regard, the JFH-1 strain
is atypical, and understanding whether it represents the global
HCV population is an important area for future research. In
this light, studying cell culture-adapted mutations may be
viewed as having limited potential; however, similar studies
with HIV variants demonstrated the value of such work in
defining the mechanisms of viral entry.
Primary attachment of HIV to CD4 lymphoid cells pro-
motes a conformational change in the viral envelope protein
gp120, which exposes epitopes that are critical for later stages
of entry (61, 70, 76). CD4 expression levels limit HIV entry,
and cell culture adaptation leads to viruses with reduced de-
pendence on CD4 and a heightened sensitivity to NAbs (4, 11,
22, 28, 57). SR-BI may fulfill a role similar to that of CD4;
indeed, Evans et al. reported that HCVcc virions bound to
CHO cells expressing SR-BI but not CD81, suggesting that
SR-BI binding residues are exposed on the particle surface
(23). However, the analogy with HIV only extends so far; HCV
association with host lipoproteins adds another level of com-
plexity, and it is becoming increasingly clear that both viral and
host components contribute to infectivity. We demonstrate
that low-density HCV particles are less sensitive to antibody
neutralization, suggesting that lipoproteins provide sanctuary
from the immune system. The G451R cell culture-adapted
mutant modulates virion interaction(s) with viral coreceptors
and NAbs, suggesting altered epitope presentation at the
virion surface. In addition, the mutation perturbed the rela-
tionship between particle density and specific infectivity. These
studies highlight the interplay between particle association
with lipoproteins, coreceptors, and NAbs, and further studies
to define how a single amino acid change can exert such pleio-
tropic effects will require a greater understanding of HCV LVP
genesis and entry into naïve target cells.
ACKNOWLEDGMENTS
We thank Takaji Wakita for JFH-1, Charles Rice for Huh-7.5 cells
and anti-NS5A 9E10 MAb, Roslyn Bill for purified full-length CD81,
FIG. 8. Association between JFH-1 particle density and sensitivity
to neutralizing antibodies. JFH-1 wt and G451R were separated on an
iodixanol gradient as detailed in the legend of Fig. 5, and the fractions
were tested for their sensitivity to neutralization by pooled HCV-
infected patient IgG (10 g/ml). Data are expressed as percent neu-
tralization calculated by comparing infectivity in the presence of HCV-
negative IgG. A positive correlation was observed between JFH-1
particle density and neutralization by pooled patient IgG (P  0.0001,
unpaired t test). Error bars indicate standard deviations from the mean
(n  4).
VOL. 82, 2008 VIRAL DETERMINANTS OF HCV CORECEPTOR DEPENDENCY 12027
Ke Hu and Margaret Goodall for anti-CD81 MAbs 2s131 and 1s201,
David Adams and David Mutimer for access to normal and HCV
patient sera, and Thierry Huby for anti-SR-BI sera and CHO-SR-BI
cells. We thank Zania Stamataki for critical reading of the manuscript.
This work was supported by PHS grants AI50798 and AI40034-14,
the MRC, and the Wellcome Trust.
REFERENCES
1. Alberti, A., L. Chemello, and L. Benvegnu. 1999. Natural history of hepatitis
C. J. Hepatol. 31(Suppl. 1):17–24.
2. Andre, P., F. Komurian-Pradel, S. Deforges, M. Perret, J. L. Berland, M.
Sodoyer, S. Pol, C. Brechot, G. Paranhos-Baccala, and V. Lotteau. 2002.
Characterization of low- and very-low-density hepatitis C virus RNA-con-
taining particles. J. Virol. 76:6919–6928.
3. Andreo, U., P. Maillard, O. Kalinina, M. Walic, E. Meurs, M. Martinot, P.
Marcellin, and A. Budkowska. 2007. Lipoprotein lipase mediates hepatitis C
virus (HCV) cell entry and inhibits HCV infection. Cell Microbiol. 9:2445–
2456.
4. Bannert, N., D. Schenten, S. Craig, and J. Sodroski. 2000. The level of CD4
expression limits infection of primary rhesus monkey macrophages by a
T-tropic simian immunodeficiency virus and macrophagetropic human im-
munodeficiency viruses. J. Virol. 74:10984–10993.
5. Barth, H., C. Schafer, M. I. Adah, F. Zhang, R. J. Linhardt, H. Toyoda, A.
Kinoshita-Toyoda, T. Toida, T. H. Van Kuppevelt, E. Depla, F. Von
Weizsacker, H. E. Blum, and T. F. Baumert. 2003. Cellular binding of
hepatitis C virus envelope glycoprotein E2 requires cell surface heparan
sulfate. J. Biol. Chem. 278:41003–41012.
6. Barth, H., E. K. Schnober, F. Zhang, R. J. Linhardt, E. Depla, B. Boson,
F. L. Cosset, A. H. Patel, H. E. Blum, and T. F. Baumert. 2006. Viral and
cellular determinants of the hepatitis C virus envelope-heparan sulfate in-
teraction. J. Virol. 80:10579–10590.
7. Bartosch, B., J. Dubuisson, and F. L. Cosset. 2003. Infectious hepatitis C
virus pseudo-particles containing functional E1-E2 envelope protein com-
plexes. J. Exp. Med. 197:633–642.
8. Bartosch, B., G. Verney, M. Dreux, P. Donot, Y. Morice, F. Penin, J. M.
Pawlotsky, D. Lavillette, and F. L. Cosset. 2005. An interplay between
hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger
receptor BI, and high-density lipoprotein promotes both enhancement of
infection and protection against neutralizing antibodies. J. Virol. 79:8217–
8229.
9. Blanchard, E., S. Belouzard, L. Goueslain, T. Wakita, J. Dubuisson, C.
Wychowski, and Y. Rouille. 2006. Hepatitis C virus entry depends on clath-
rin-mediated endocytosis. J. Virol. 80:6964–6972.
10. Blight, K. J., J. A. McKeating, and C. M. Rice. 2002. Highly permissive cell
lines for subgenomic and genomic hepatitis C virus RNA replication. J. Vi-
rol. 76:13001–13014.
11. Blish, C. A., M. A. Nguyen, and J. Overbaugh. 2008. Enhancing exposure of
HIV-1 neutralization epitopes through mutations in gp41. PLoS Med. 5:e9.
12. Catanese, M. T., R. Graziani, T. von Hahn, M. Moreau, T. Huby, G. Paonessa,
C. Santini, A. Luzzago, C. M. Rice, R. Cortese, A. Vitelli, and A. Nicosia. 2007.
High-avidity monoclonal antibodies against the human scavenger class B type I
receptor efficiently block hepatitis C virus infection in the presence of high-
density lipoprotein. J. Virol. 81:8063–8071.
13. Chang, K. S., J. Jiang, Z. Cai, and G. Luo. 2007. Human apolipoprotein E
is required for infectivity and production of hepatitis C virus in cell culture.
J. Virol. 81:13783–13793.
14. Clayton, R. F., A. Owsianka, J. Aitken, S. Graham, D. Bhella, and A. H.
Patel. 2002. Analysis of antigenicity and topology of E2 glycoprotein present
on recombinant hepatitis C virus-like particles. J. Virol. 76:7672–7682.
15. Codran, A., C. Royer, D. Jaeck, M. Bastien-Valle, T. F. Baumert, M. P.
Kieny, C. A. Pereira, and J. P. Martin. 2006. Entry of hepatitis C virus
pseudotypes into primary human hepatocytes by clathrin-dependent endo-
cytosis. J. Gen. Virol. 87:2583–2593.
16. Cook, L., K. W. Ng, A. Bagabag, L. Corey, and K. R. Jerome. 2004. Use of
the MagNA pure LC automated nucleic acid extraction system followed by
real-time reverse transcription-PCR for ultrasensitive quantitation of hepa-
titis C virus RNA. J. Clin. Microbiol. 42:4130–4136.
17. Dreux, M., T. Pietschmann, C. Granier, C. Voisset, S. Ricard-Blum, P. E.
Mangeot, Z. Keck, S. Foung, N. Vu-Dac, J. Dubuisson, R. Bartenschlager, D.
Lavillette, and F. L. Cosset. 2006. High density lipoprotein inhibits hepatitis
C virus-neutralizing antibodies by stimulating cell entry via activation of the
scavenger receptor BI. J. Biol. Chem. 281:18285–18295.
18. Drummer, H. E., I. Boo, A. L. Maerz, and P. Poumbourios. 2006. A con-
served Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus gly-
coprotein E2 is a determinant of CD81 binding and viral entry. J. Virol.
80:7844–7853.
19. Drummer, H. E., K. A. Wilson, and P. Poumbourios. 2005. Determinants of
CD81 dimerization and interaction with hepatitis C virus glycoprotein E2.
Biochem. Biophys. Res. Commun. 328:251–257.
20. Drummer, H. E., K. A. Wilson, and P. Poumbourios. 2002. Identification of
the hepatitis C virus E2 glycoprotein binding site on the large extracellular
loop of CD81. J. Virol. 76:11143–11147.
21. Dubuisson, J., F. Helle, and L. Cocquerel. 2008. Early steps of the hepatitis
C virus life cycle. Cell Microbiol. 10:821–827.
22. Dumonceaux, J., C. Chanel, S. Valente, L. Quivet, P. Briand, and U. Hazan.
1999. Mutations in the env gene of human immunodeficiency virus type 1
NDK isolates and the use of African green monkey CXCR4 as a co-receptor
in COS-7 cells. J. Gen. Virol. 80:1975–1982.
23. Evans, M. J., T. von Hahn, D. M. Tscherne, A. J. Syder, M. Panis, B. Wolk,
T. Hatziioannou, J. A. McKeating, P. D. Bieniasz, and C. M. Rice. 2007.
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.
Nature 446:801–805.
24. Flint, M., C. Maidens, L. D. Loomis-Price, C. Shotton, J. Dubuisson, P.
Monk, A. Higginbottom, S. Levy, and J. A. McKeating. 1999. Characteriza-
tion of hepatitis C virus E2 glycoprotein interaction with a putative cellular
receptor, CD81. J. Virol. 73:6235–6244.
25. Flint, M., T. von Hahn, J. Zhang, M. Farquhar, C. T. Jones, P. Balfe, C. M.
Rice, and J. A. McKeating. 2006. Diverse CD81 proteins support hepatitis C
virus infection. J. Virol.
26. Gastaminza, P., G. Cheng, S. Wieland, J. Zhong, W. Liao, and F. V. Chisari.
2008. Cellular determinants of hepatitis C virus assembly, maturation, deg-
radation, and secretion. J. Virol. 82:2120–2129.
27. Grove, J., T. Huby, Z. Stamataki, T. Vanwolleghem, P. Meuleman, M. Far-
quhar, A. Schwarz, M. Moreau, J. S. Owen, G. Leroux-Roels, P. Balfe, and
J. A. McKeating. 2007. Scavenger receptor BI and BII expression levels
modulate hepatitis C virus infectivity. J. Virol. 81:3162–3169.
28. Hoffman, T. L., C. C. LaBranche, W. Zhang, G. Canziani, J. Robinson, I.
Chaiken, J. A. Hoxie, and R. W. Doms. 1999. Stable exposure of the core-
ceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc.
Natl. Acad. Sci. USA 96:6359–6364.
29. Hsu, M., J. Zhang, M. Flint, C. Logvinoff, C. Cheng-Mayer, C. M. Rice, and
J. A. McKeating. 2003. Hepatitis C virus glycoproteins mediate pH-depen-
dent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci.
USA 100:7271–7276.
30. Huang, H., F. Sun, D. M. Owen, W. Li, Y. Chen, M. Gale, Jr., and J. Ye. 2007.
Hepatitis C virus production by human hepatocytes dependent on assembly
and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. USA
104:5848–5853.
31. Kapadia, S. B., H. Barth, T. Baumert, J. A. McKeating, and F. V. Chisari.
2007. Initiation of hepatitis C virus infection is dependent on cholesterol and
cooperativity between CD81 and scavenger receptor B type I. J. Virol.
81:374–383.
32. Kaul, A., I. Woerz, P. Meuleman, G. Leroux-Roels, and R. Bartenschlager.
2007. Cell culture adaptation of hepatitis C virus and in vivo viability of an
adapted variant. J. Virol. 81:13168–13179.
33. Keck, Z. Y., T. K. Li, J. Xia, M. Gal-Tanamy, O. Olson, S. H. Li, A. H. Patel,
J. K. Ball, S. M. Lemon, and S. K. Foung. 2008. Definition of a conserved
immunodominant domain on hepatitis C virus E2 glycoprotein by neutral-
izing human monoclonal antibodies. J. Virol. 82:6061–6066.
34. Keck, Z. Y., O. Olson, M. Gal-Tanamy, J. Xia, A. H. Patel, M. Dreux, F. L.
Cosset, S. M. Lemon, and S. K. Foung. 2008. A point mutation leading to
hepatitis C virus escape from neutralization by a monoclonal antibody to a
conserved conformational epitope. J. Virol. 82:6067–6072.
35. Keck, Z. Y., J. Xia, Z. Cai, T. K. Li, A. M. Owsianka, A. H. Patel, G. Luo, and
S. K. Foung. 2007. Immunogenic and functional organization of hepatitis C
virus (HCV) glycoprotein E2 on infectious HCV virions. J. Virol. 81:1043–
1047.
36. Krieger, M. 2001. Scavenger receptor class B type I is a multiligand HDL
receptor that influences diverse physiologic systems. J. Clin. Investig. 108:
793–797.
37. Lai, W. K., P. J. Sun, J. Zhang, A. Jennings, P. F. Lalor, S. Hubscher, J. A.
McKeating, and D. H. Adams. 2006. Expression of DC-SIGN and DC-
SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C
virus particles. Am. J. Pathol. 169:200–208.
38. Lavillette, D., A. W. Tarr, C. Voisset, P. Donot, B. Bartosch, C. Bain, A. H.
Patel, J. Dubuisson, J. K. Ball, and F. L. Cosset. 2005. Characterization of
host-range and cell entry properties of the major genotypes and subtypes of
hepatitis C virus. Hepatology 41:265–274.
39. Levy, S., S. C. Todd, and H. T. Maecker. 1998. CD81 (TAPA-1): a molecule
involved in signal transduction and cell adhesion in the immune system.
Annu. Rev. Immunol. 16:89–109.
40. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen,
C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and
C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture.
Science 309:623–626.
41. Lindenbach, B. D., P. Meuleman, A. Ploss, T. Vanwolleghem, A. J. Syder,
J. A. McKeating, R. E. Lanford, S. M. Feinstone, M. E. Major, G. Leroux-
Roels, and C. M. Rice. 2006. Cell culture-grown hepatitis C virus is infectious
in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. USA 103:3805–
3809.
42. Lozach, P. Y., A. Amara, B. Bartosch, J. L. Virelizier, F. Arenzana-Seisdedos,
F. L. Cosset, and R. Altmeyer. 2004. C-type lectins L-SIGN and DC-SIGN
12028 GROVE ET AL. J. VIROL.
capture and transmit infectious hepatitis C virus pseudotype particles.
J. Biol. Chem. 279:32035–32045.
43. Lozach, P. Y., H. Lortat-Jacob, A. de Lacroix de Lavalette, I. Staropoli, S.
Foung, A. Amara, C. Houles, F. Fieschi, O. Schwartz, J. L. Virelizier, F.
Arenzana-Seisdedos, and R. Altmeyer. 2003. DC-SIGN and L-SIGN are high
affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem.
278:20358–20366.
44. Maillard, P., T. Huby, U. Andreo, M. Moreau, J. Chapman, and A. Budkowska.
2006. The interaction of natural hepatitis C virus with human scavenger receptor
SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J. 20:735–
737.
45. McKeating, J. A., L. Q. Zhang, C. Logvinoff, M. Flint, J. Zhang, J. Yu, D.
Butera, D. D. Ho, L. B. Dustin, C. M. Rice, and P. Balfe. 2004. Diverse
hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent
manner. J. Virol. 78:8496–8505.
46. Mee, C. J., J. Grove, H. J. Harris, K. Hu, P. Balfe, and J. A. McKeating. 2008.
Effect of cell polarization on hepatitis C virus entry. J. Virol. 82:461–470.
47. Meertens, L., C. Bertaux, and T. Dragic. 2006. Hepatitis C Virus entry
requires a critical post-internalization step and delivery to early endosomes
via clathrin coated vesicles. J. Virol. 80:11571–11578.
48. Miyanari, Y., K. Atsuzawa, N. Usuda, K. Watashi, T. Hishiki, M. Zayas, R.
Bartenschlager, T. Wakita, M. Hijikata, and K. Shimotohno. 2007. The lipid
droplet is an important organelle for hepatitis C virus production. Nat. Cell
Biol. 9:1089–1097.
49. Molina, S., V. Castet, C. Fournier-Wirth, L. Pichard-Garcia, R. Avner, D.
Harats, J. Roitelman, R. Barbaras, P. Graber, P. Ghersa, M. Smolarsky, A.
Funaro, F. Malavasi, D. Larrey, J. Coste, J. M. Fabre, A. Sa-Cunha, and P.
Maurel. 2007. The low-density lipoprotein receptor plays a role in the in-
fection of primary human hepatocytes by hepatitis C virus. J. Hepatol.
46:411–419.
50. Molina, S., V. Castet, L. Pichard-Garcia, C. Wychowski, E. Meurs, J. M.
Pascussi, C. Sureau, J. M. Fabre, A. Sacunha, D. Larrey, J. Dubuisson, J.
Coste, J. McKeating, P. Maurel, and C. Fournier-Wirth. 2008. Serum-de-
rived hepatitis C virus infection of primary human hepatocytes is tetraspanin
CD81 dependent. J. Virol. 82:569–574.
51. Morikawa, K., Z. Zhao, T. Date, M. Miyamoto, A. Murayama, D. Akazawa,
J. Tanabe, S. Sone, and T. Wakita. 2007. The roles of CD81 and glycosamino-
glycans in the adsorption and uptake of infectious HCV particles. J. Med.
Virol. 79:714–723.
52. Nielsen, S. U., M. F. Bassendine, A. D. Burt, D. J. Bevitt, and G. L. Toms.
2004. Characterization of the genome and structural proteins of hepatitis C
virus resolved from infected human liver. J. Gen. Virol. 85:1497–1507.
53. Nielsen, S. U., M. F. Bassendine, A. D. Burt, C. Martin, W. Pumeechockchai,
and G. L. Toms. 2006. Association between hepatitis C virus and very-low-
density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients.
J. Virol. 80:2418–2428.
54. Owsianka, A. M., A. W. Tarr, Z. Y. Keck, T. K. Li, J. Witteveldt, R. Adair,
S. K. Foung, J. K. Ball, and A. H. Patel. 2008. Broadly neutralizing human
monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol.
89:653–659.
55. Owsianka, A. M., J. M. Timms, A. W. Tarr, R. J. Brown, T. P. Hickling, A.
Szwejk, K. Bienkowska-Szewczyk, B. J. Thomson, A. H. Patel, and J. K. Ball.
2006. Identification of conserved residues in the E2 envelope glycoprotein of
the hepatitis C virus that are critical for CD81 binding. J. Virol. 80:8695–
8704.
56. Pileri, P., Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, A. J.
Weiner, M. Houghton, D. Rosa, G. Grandi, and S. Abrignani. 1998. Binding
of hepatitis C virus to CD81. Science 282:938–941.
57. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998.
Effects of CCR5 and CD4 cell surface concentrations on infections by mac-
rophagetropic isolates of human immunodeficiency virus type 1. J. Virol.
72:2855–2864.
58. Pohlmann, S., J. Zhang, F. Baribaud, Z. Chen, G. J. Leslie, G. Lin, A.
Granelli-Piperno, R. W. Doms, C. M. Rice, and J. A. McKeating. 2003.
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR.
J. Virol. 77:4070–4080.
59. Rothwangl, K. B., B. Manicassamy, S. L. Uprichard, and L. Rong. 2008.
Dissecting the role of putative CD81 binding regions of E2 in mediating
HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.
Virol. J. 5:46.
60. Russell, R. S., J. C. Meunier, S. Takikawa, K. Faulk, R. E. Engle, J. Bukh,
R. H. Purcell, and S. U. Emerson. 2008. Advantages of a single-cycle pro-
duction assay to study cell culture-adaptive mutations of hepatitis C virus.
Proc. Natl. Acad. Sci. USA 105:4370–4375.
61. Sattentau, Q. J., J. P. Moore, F. Vignaux, F. Traincard, and P. Poignard.
1993. Conformational changes induced in the envelope glycoproteins of the
human and simian immunodeficiency viruses by soluble receptor binding.
J. Virol. 67:7383–7393.
62. Scarselli, E., H. Ansuini, R. Cerino, R. M. Roccasecca, S. Acali, G. Filocamo, C.
Traboni, A. Nicosia, R. Cortese, and A. Vitelli. 2002. The human scavenger
receptor class B type I is a novel candidate receptor for the hepatitis C virus.
EMBO J. 21:5017–5025.
63. Shotton, C., C. Arnold, Q. Sattentau, J. Sodroski, and J. A. McKeating. 1995.
Identification and characterization of monoclonal antibodies specific for
polymorphic antigenic determinants within the V2 region of the human
immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 69:222–230.
64. Silver, D. L. 2004. SR-BI and protein-protein interactions in hepatic high
density lipoprotein metabolism. Rev. Endocr. Metab. Disord. 5:327–333.
65. Stamataki, Z., J. Grove, P. Balfe, and J. A. McKeating. 2008. Hepatitis C
virus entry and neutralization. Clin. Liver Dis. 12:693–712.
66. Tang, Y., Q. Wang, and Y. M. Saif. 2005. Development of a ssRNA internal
control template reagent for a multiplex RT-PCR to detect turkey astrovi-
ruses. J. Virol. Methods 126:81–86.
67. Thomssen, R., S. Bonk, C. Propfe, K. H. Heermann, H. G. Kochel, and A. Uy.
1992. Association of hepatitis C virus in human sera with beta-lipoprotein.
Med. Microbiol. Immunol. 181:293–300.
68. Thomssen, R., S. Bonk, and A. Thiele. 1993. Density heterogeneities of
hepatitis C virus in human sera due to the binding of beta-lipoproteins and
immunoglobulins. Med. Microbiol. Immunol. 182:329–334.
69. Timpe, J. M., Z. Stamataki, A. Jennings, K. Hu, M. J. Farquhar, H. J. Harris,
A. Schwarz, I. Desombere, G. L. Roels, P. Balfe, and J. A. McKeating. 2008.
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of
neutralizing antibodies. Hepatology 47:17–24.
70. Trkola, A., T. Dragic, J. Arthos, J. M. Binley, W. C. Olson, G. P. Allaway, C.
Cheng-Mayer, J. Robinson, P. J. Maddon, and J. P. Moore. 1996. CD4-
dependent, antibody-sensitive interactions between HIV-1 and its co-recep-
tor CCR-5. Nature 384:184–187.
71. Tscherne, D. M., C. T. Jones, M. J. Evans, B. D. Lindenbach, J. A. McKeating,
and C. M. Rice. 2006. Time- and temperature-dependent activation of hepatitis
C virus for low-pH-triggered entry. J. Virol. 80:1734–1741.
72. Voisset, C., N. Callens, E. Blanchard, A. Op De Beeck, J. Dubuisson, and N.
Vu-Dac. 2005. High density lipoproteins facilitate hepatitis C virus entry
through the scavenger receptor class B type I. J. Biol. Chem. 280:7793–7799.
73. von Hahn, T., B. D. Lindenbach, A. Boullier, O. Quehenberger, M. Paulson,
C. M. Rice, and J. A. McKeating. 2006. Oxidized low-density lipoprotein
inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology
43:932–942.
74. von Hahn, T., and C. M. Rice. 2008. Hepatitis C virus entry. J. Biol. Chem.
283:3689–3693.
75. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K.
Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager,
and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue
culture from a cloned viral genome. Nat. Med. 11:791–796.
76. Wu, L., N. P. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti,
A. A. Cardoso, E. Desjardin, W. Newman, C. Gerard, and J. Sodroski. 1996.
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the
chemokine receptor CCR-5. Nature 384:179–183.
77. Wunschmann, S., J. D. Medh, D. Klinzmann, W. N. Schmidt, and J. T.
Stapleton. 2000. Characterization of hepatitis C virus (HCV) and HCV E2
interactions with CD81 and the low-density lipoprotein receptor. J. Virol.
74:10055–10062.
78. Zeisel, M. B., G. Koutsoudakis, E. K. Schnober, A. Haberstroh, H. E. Blum,
F. L. Cosset, T. Wakita, D. Jaeck, M. Doffoel, C. Royer, E. Soulier, E.
Schvoerer, C. Schuster, F. Stoll-Keller, R. Bartenschlager, T. Pietschmann,
H. Barth, and T. F. Baumert. 2007. Scavenger receptor class B type I is a key
host factor for hepatitis C virus infection required for an entry step closely
linked to CD81. Hepatology 46:1722–1731.
79. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F.
Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust
hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102:9294–
9299.
80. Zhong, J., P. Gastaminza, J. Chung, Z. Stamataki, M. Isogawa, G. Cheng,
J. A. McKeating, and F. V. Chisari. 2006. Persistent hepatitis C virus infec-
tion in vitro: coevolution of virus and host. J. Virol. 80:11082–11093.
VOL. 82, 2008 VIRAL DETERMINANTS OF HCV CORECEPTOR DEPENDENCY 12029
